Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PACB) Stock Competitors & Peer Comparison
See (PACB) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PACB | $1.32 | -4.35% | 396.5M | -0.59 | -$2.23 | N/A |
| ABT | $131.87 | -0.54% | 229.5B | 16.55 | $7.97 | +1.75% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $105.11 | -1.00% | 155.8B | 62.58 | $1.68 | N/A |
| SYK | $390.88 | -0.85% | 149.4B | 51.63 | $7.57 | +0.85% |
| MDT | $92.04 | -0.72% | 117.9B | 25.42 | $3.62 | +3.05% |
| EW | $80.86 | -1.19% | 47.5B | 33.85 | $2.39 | N/A |
| DXCM | $75.96 | -7.66% | 29.8B | 53.49 | $1.42 | N/A |
| PHG | $27.60 | -2.61% | 25.6B | 145.21 | $0.19 | +3.21% |
| STE | $248.48 | -1.35% | 24.5B | 37.92 | $6.55 | +0.92% |
Stock Comparison
PACB vs ABT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ABT has a market cap of 229.5B. Regarding current trading prices, PACB is priced at $1.32, while ABT trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ABT's P/E ratio is 16.55. In terms of profitability, PACB's ROE is -1.89%, compared to ABT's ROE of +0.32%. Regarding short-term risk, PACB is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check ABT's competition here
PACB vs BSX-PA Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PACB is priced at $1.32, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PACB's ROE is -1.89%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, PACB is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check BSX-PA's competition here
PACB vs BSX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BSX has a market cap of 155.8B. Regarding current trading prices, PACB is priced at $1.32, while BSX trades at $105.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BSX's P/E ratio is 62.58. In terms of profitability, PACB's ROE is -1.89%, compared to BSX's ROE of +0.12%. Regarding short-term risk, PACB is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check BSX's competition here
PACB vs SYK Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SYK has a market cap of 149.4B. Regarding current trading prices, PACB is priced at $1.32, while SYK trades at $390.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SYK's P/E ratio is 51.63. In terms of profitability, PACB's ROE is -1.89%, compared to SYK's ROE of +0.14%. Regarding short-term risk, PACB is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check SYK's competition here
PACB vs MDT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, MDT has a market cap of 117.9B. Regarding current trading prices, PACB is priced at $1.32, while MDT trades at $92.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas MDT's P/E ratio is 25.42. In terms of profitability, PACB's ROE is -1.89%, compared to MDT's ROE of +0.13%. Regarding short-term risk, PACB is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check MDT's competition here
PACB vs EW Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, EW has a market cap of 47.5B. Regarding current trading prices, PACB is priced at $1.32, while EW trades at $80.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas EW's P/E ratio is 33.85. In terms of profitability, PACB's ROE is -1.89%, compared to EW's ROE of +0.41%. Regarding short-term risk, PACB is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check EW's competition here
PACB vs DXCM Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, DXCM has a market cap of 29.8B. Regarding current trading prices, PACB is priced at $1.32, while DXCM trades at $75.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas DXCM's P/E ratio is 53.49. In terms of profitability, PACB's ROE is -1.89%, compared to DXCM's ROE of +0.26%. Regarding short-term risk, PACB is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check DXCM's competition here
PACB vs PHG Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, PHG has a market cap of 25.6B. Regarding current trading prices, PACB is priced at $1.32, while PHG trades at $27.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas PHG's P/E ratio is 145.21. In terms of profitability, PACB's ROE is -1.89%, compared to PHG's ROE of +0.01%. Regarding short-term risk, PACB is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check PHG's competition here
PACB vs STE Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, STE has a market cap of 24.5B. Regarding current trading prices, PACB is priced at $1.32, while STE trades at $248.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas STE's P/E ratio is 37.92. In terms of profitability, PACB's ROE is -1.89%, compared to STE's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check STE's competition here
PACB vs PODD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, PODD has a market cap of 23.2B. Regarding current trading prices, PACB is priced at $1.32, while PODD trades at $329.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas PODD's P/E ratio is 100.61. In terms of profitability, PACB's ROE is -1.89%, compared to PODD's ROE of +0.18%. Regarding short-term risk, PACB is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check PODD's competition here
PACB vs ZBH Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ZBH has a market cap of 21.3B. Regarding current trading prices, PACB is priced at $1.32, while ZBH trades at $107.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ZBH's P/E ratio is 26.17. In terms of profitability, PACB's ROE is -1.89%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, PACB is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check ZBH's competition here
PACB vs ABMD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PACB is priced at $1.32, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PACB's ROE is -1.89%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check ABMD's competition here
PACB vs SNN Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SNN has a market cap of 16.3B. Regarding current trading prices, PACB is priced at $1.32, while SNN trades at $37.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SNN's P/E ratio is 33.21. In terms of profitability, PACB's ROE is -1.89%, compared to SNN's ROE of +0.09%. Regarding short-term risk, PACB is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check SNN's competition here
PACB vs SWAV Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PACB is priced at $1.32, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PACB's ROE is -1.89%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PACB is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check SWAV's competition here
PACB vs ALGN Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ALGN has a market cap of 10.5B. Regarding current trading prices, PACB is priced at $1.32, while ALGN trades at $144.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ALGN's P/E ratio is 24.49. In terms of profitability, PACB's ROE is -1.89%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check ALGN's competition here
PACB vs PEN Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, PEN has a market cap of 10.3B. Regarding current trading prices, PACB is priced at $1.32, while PEN trades at $264.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas PEN's P/E ratio is 69.75. In terms of profitability, PACB's ROE is -1.89%, compared to PEN's ROE of +0.12%. Regarding short-term risk, PACB is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check PEN's competition here
PACB vs GMED Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, GMED has a market cap of 8.3B. Regarding current trading prices, PACB is priced at $1.32, while GMED trades at $61.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas GMED's P/E ratio is 23.81. In terms of profitability, PACB's ROE is -1.89%, compared to GMED's ROE of +0.09%. Regarding short-term risk, PACB is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check GMED's competition here
PACB vs BIO Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BIO has a market cap of 8B. Regarding current trading prices, PACB is priced at $1.32, while BIO trades at $297.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BIO's P/E ratio is 26.81. In terms of profitability, PACB's ROE is -1.89%, compared to BIO's ROE of +0.05%. Regarding short-term risk, PACB is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check BIO's competition here
PACB vs BIO-B Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BIO-B has a market cap of 6.7B. Regarding current trading prices, PACB is priced at $1.32, while BIO-B trades at $247.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, PACB's ROE is -1.89%, compared to BIO-B's ROE of +0.05%. Regarding short-term risk, PACB is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check BIO-B's competition here
PACB vs IRTC Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, IRTC has a market cap of 5.3B. Regarding current trading prices, PACB is priced at $1.32, while IRTC trades at $165.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas IRTC's P/E ratio is -56.55. In terms of profitability, PACB's ROE is -1.89%, compared to IRTC's ROE of -1.05%. Regarding short-term risk, PACB is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check IRTC's competition here
PACB vs GKOS Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, GKOS has a market cap of 5.3B. Regarding current trading prices, PACB is priced at $1.32, while GKOS trades at $91.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas GKOS's P/E ratio is -56.87. In terms of profitability, PACB's ROE is -1.89%, compared to GKOS's ROE of -0.13%. Regarding short-term risk, PACB is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check GKOS's competition here
PACB vs BRKR Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BRKR has a market cap of 5.3B. Regarding current trading prices, PACB is priced at $1.32, while BRKR trades at $34.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BRKR's P/E ratio is 66.56. In terms of profitability, PACB's ROE is -1.89%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, PACB is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check BRKR's competition here
PACB vs NARI Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PACB is priced at $1.32, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas NARI's P/E ratio is -59.24. In terms of profitability, PACB's ROE is -1.89%, compared to NARI's ROE of -0.17%. Regarding short-term risk, PACB is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check NARI's competition here
PACB vs TMDX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, TMDX has a market cap of 3.9B. Regarding current trading prices, PACB is priced at $1.32, while TMDX trades at $114.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas TMDX's P/E ratio is 57.77. In terms of profitability, PACB's ROE is -1.89%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, PACB is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check TMDX's competition here
PACB vs ITGR Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ITGR has a market cap of 3.8B. Regarding current trading prices, PACB is priced at $1.32, while ITGR trades at $108.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ITGR's P/E ratio is 46.51. In terms of profitability, PACB's ROE is -1.89%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, PACB is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check ITGR's competition here
PACB vs AXNX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PACB is priced at $1.32, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PACB's ROE is -1.89%, compared to AXNX's ROE of -0.02%. Regarding short-term risk, PACB is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check AXNX's competition here
PACB vs LIVN Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, LIVN has a market cap of 3.1B. Regarding current trading prices, PACB is priced at $1.32, while LIVN trades at $56.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas LIVN's P/E ratio is -14.52. In terms of profitability, PACB's ROE is -1.89%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, PACB is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check LIVN's competition here
PACB vs INSP Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, INSP has a market cap of 2.7B. Regarding current trading prices, PACB is priced at $1.32, while INSP trades at $92.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas INSP's P/E ratio is 53.41. In terms of profitability, PACB's ROE is -1.89%, compared to INSP's ROE of +0.08%. Regarding short-term risk, PACB is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check INSP's competition here
PACB vs ATEC Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ATEC has a market cap of 2.3B. Regarding current trading prices, PACB is priced at $1.32, while ATEC trades at $15.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ATEC's P/E ratio is -14.02. In terms of profitability, PACB's ROE is -1.89%, compared to ATEC's ROE of -2.52%. Regarding short-term risk, PACB is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check ATEC's competition here
PACB vs PRCT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, PRCT has a market cap of 2.2B. Regarding current trading prices, PACB is priced at $1.32, while PRCT trades at $39.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas PRCT's P/E ratio is -25.53. In terms of profitability, PACB's ROE is -1.89%, compared to PRCT's ROE of -0.24%. Regarding short-term risk, PACB is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check PRCT's competition here
PACB vs NUVA Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PACB is priced at $1.32, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PACB's ROE is -1.89%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PACB is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check NUVA's competition here
PACB vs AORT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, AORT has a market cap of 2.1B. Regarding current trading prices, PACB is priced at $1.32, while AORT trades at $43.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas AORT's P/E ratio is -101.23. In terms of profitability, PACB's ROE is -1.89%, compared to AORT's ROE of -0.06%. Regarding short-term risk, PACB is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check AORT's competition here
PACB vs UFPT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, PACB is priced at $1.32, while UFPT trades at $220.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas UFPT's P/E ratio is 25.63. In terms of profitability, PACB's ROE is -1.89%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, PACB is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check UFPT's competition here
PACB vs CNMD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, PACB is priced at $1.32, while CNMD trades at $54.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas CNMD's P/E ratio is 15.34. In terms of profitability, PACB's ROE is -1.89%, compared to CNMD's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check CNMD's competition here
PACB vs SSII Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SSII has a market cap of 1.4B. Regarding current trading prices, PACB is priced at $1.32, while SSII trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SSII's P/E ratio is -116.33. In terms of profitability, PACB's ROE is -1.89%, compared to SSII's ROE of -0.71%. Regarding short-term risk, PACB is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check SSII's competition here
PACB vs HSKA Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PACB is priced at $1.32, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PACB's ROE is -1.89%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PACB is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check HSKA's competition here
PACB vs AHCO Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, PACB is priced at $1.32, while AHCO trades at $9.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas AHCO's P/E ratio is 17.09. In terms of profitability, PACB's ROE is -1.89%, compared to AHCO's ROE of +0.05%. Regarding short-term risk, PACB is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check AHCO's competition here
PACB vs ESTA Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, PACB is priced at $1.32, while ESTA trades at $40.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ESTA's P/E ratio is -13.20. In terms of profitability, PACB's ROE is -1.89%, compared to ESTA's ROE of -2.41%. Regarding short-term risk, PACB is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check ESTA's competition here
PACB vs SILK Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.32, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SILK's P/E ratio is -18.96. In terms of profitability, PACB's ROE is -1.89%, compared to SILK's ROE of -0.20%. Regarding short-term risk, PACB is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check SILK's competition here
PACB vs IART Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.32, while IART trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas IART's P/E ratio is -2.18. In terms of profitability, PACB's ROE is -1.89%, compared to IART's ROE of -0.36%. Regarding short-term risk, PACB is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check IART's competition here
PACB vs FNA Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.32, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas FNA's P/E ratio is -19.83. In terms of profitability, PACB's ROE is -1.89%, compared to FNA's ROE of -0.36%. Regarding short-term risk, PACB is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check FNA's competition here
PACB vs INMD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, INMD has a market cap of 1B. Regarding current trading prices, PACB is priced at $1.32, while INMD trades at $14.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas INMD's P/E ratio is 6.12. In terms of profitability, PACB's ROE is -1.89%, compared to INMD's ROE of +0.27%. Regarding short-term risk, PACB is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check INMD's competition here
PACB vs IRMD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, IRMD has a market cap of 909.5M. Regarding current trading prices, PACB is priced at $1.32, while IRMD trades at $71.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas IRMD's P/E ratio is 44.41. In terms of profitability, PACB's ROE is -1.89%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PACB is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check IRMD's competition here
PACB vs CSII Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PACB is priced at $1.32, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas CSII's P/E ratio is -20.83. In terms of profitability, PACB's ROE is -1.89%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PACB is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check CSII's competition here
PACB vs TNDM Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, TNDM has a market cap of 818.3M. Regarding current trading prices, PACB is priced at $1.32, while TNDM trades at $12.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas TNDM's P/E ratio is -3.93. In terms of profitability, PACB's ROE is -1.89%, compared to TNDM's ROE of -1.04%. Regarding short-term risk, PACB is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check TNDM's competition here
PACB vs CRY Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, PACB is priced at $1.32, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas CRY's P/E ratio is 425.71. In terms of profitability, PACB's ROE is -1.89%, compared to CRY's ROE of -0.05%. Regarding short-term risk, PACB is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check CRY's competition here
PACB vs SIBN Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SIBN has a market cap of 692.4M. Regarding current trading prices, PACB is priced at $1.32, while SIBN trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SIBN's P/E ratio is -28.16. In terms of profitability, PACB's ROE is -1.89%, compared to SIBN's ROE of -0.14%. Regarding short-term risk, PACB is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check SIBN's competition here
PACB vs AXGN Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, AXGN has a market cap of 680.5M. Regarding current trading prices, PACB is priced at $1.32, while AXGN trades at $14.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas AXGN's P/E ratio is -147.90. In terms of profitability, PACB's ROE is -1.89%, compared to AXGN's ROE of -0.04%. Regarding short-term risk, PACB is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check AXGN's competition here
PACB vs APEN Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PACB is priced at $1.32, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas APEN's P/E ratio is -9.43. In terms of profitability, PACB's ROE is -1.89%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PACB is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check APEN's competition here
PACB vs OFIX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, OFIX has a market cap of 572.7M. Regarding current trading prices, PACB is priced at $1.32, while OFIX trades at $14.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas OFIX's P/E ratio is -4.57. In terms of profitability, PACB's ROE is -1.89%, compared to OFIX's ROE of -0.25%. Regarding short-term risk, PACB is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check OFIX's competition here
PACB vs AVNS Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, AVNS has a market cap of 537.6M. Regarding current trading prices, PACB is priced at $1.32, while AVNS trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas AVNS's P/E ratio is -1.16. In terms of profitability, PACB's ROE is -1.89%, compared to AVNS's ROE of -0.50%. Regarding short-term risk, PACB is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check AVNS's competition here
PACB vs ZIMV Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ZIMV has a market cap of 534.7M. Regarding current trading prices, PACB is priced at $1.32, while ZIMV trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ZIMV's P/E ratio is -27.48. In terms of profitability, PACB's ROE is -1.89%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, PACB is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check ZIMV's competition here
PACB vs CTKB Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, CTKB has a market cap of 522.9M. Regarding current trading prices, PACB is priced at $1.32, while CTKB trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas CTKB's P/E ratio is -82.20. In terms of profitability, PACB's ROE is -1.89%, compared to CTKB's ROE of -0.02%. Regarding short-term risk, PACB is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check CTKB's competition here
PACB vs KIDS Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, KIDS has a market cap of 508.7M. Regarding current trading prices, PACB is priced at $1.32, while KIDS trades at $20.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas KIDS's P/E ratio is -11.27. In terms of profitability, PACB's ROE is -1.89%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PACB is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check KIDS's competition here
PACB vs SRDX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SRDX has a market cap of 504.8M. Regarding current trading prices, PACB is priced at $1.32, while SRDX trades at $35.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SRDX's P/E ratio is -28.48. In terms of profitability, PACB's ROE is -1.89%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, PACB is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check SRDX's competition here
PACB vs BVS Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BVS has a market cap of 497.7M. Regarding current trading prices, PACB is priced at $1.32, while BVS trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BVS's P/E ratio is 248.00. In terms of profitability, PACB's ROE is -1.89%, compared to BVS's ROE of -0.00%. Regarding short-term risk, PACB is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check BVS's competition here
PACB vs VREX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, VREX has a market cap of 473.1M. Regarding current trading prices, PACB is priced at $1.32, while VREX trades at $11.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas VREX's P/E ratio is -3.53. In terms of profitability, PACB's ROE is -1.89%, compared to VREX's ROE of -0.25%. Regarding short-term risk, PACB is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check VREX's competition here
PACB vs TMCI Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, TMCI has a market cap of 471.9M. Regarding current trading prices, PACB is priced at $1.32, while TMCI trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas TMCI's P/E ratio is -9.46. In terms of profitability, PACB's ROE is -1.89%, compared to TMCI's ROE of -0.47%. Regarding short-term risk, PACB is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check TMCI's competition here
PACB vs SMLR Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SMLR has a market cap of 444.4M. Regarding current trading prices, PACB is priced at $1.32, while SMLR trades at $30.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SMLR's P/E ratio is 6.58. In terms of profitability, PACB's ROE is -1.89%, compared to SMLR's ROE of +0.17%. Regarding short-term risk, PACB is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check SMLR's competition here
PACB vs BFLY-WT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BFLY-WT has a market cap of 426.4M. Regarding current trading prices, PACB is priced at $1.32, while BFLY-WT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, PACB's ROE is -1.89%, compared to BFLY-WT's ROE of -0.31%. Regarding short-term risk, PACB is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check BFLY-WT's competition here
PACB vs CBLL Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, CBLL has a market cap of 419.4M. Regarding current trading prices, PACB is priced at $1.32, while CBLL trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas CBLL's P/E ratio is -3.17. In terms of profitability, PACB's ROE is -1.89%, compared to CBLL's ROE of -0.48%. Regarding short-term risk, PACB is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check CBLL's competition here
PACB vs BFLY Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BFLY has a market cap of 390.2M. Regarding current trading prices, PACB is priced at $1.32, while BFLY trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BFLY's P/E ratio is -5.54. In terms of profitability, PACB's ROE is -1.89%, compared to BFLY's ROE of -0.31%. Regarding short-term risk, PACB is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check BFLY's competition here
PACB vs SENS Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SENS has a market cap of 366.6M. Regarding current trading prices, PACB is priced at $1.32, while SENS trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SENS's P/E ratio is -4.50. In terms of profitability, PACB's ROE is -1.89%, compared to SENS's ROE of -12.27%. Regarding short-term risk, PACB is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check SENS's competition here
PACB vs SNWV Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SNWV has a market cap of 365.5M. Regarding current trading prices, PACB is priced at $1.32, while SNWV trades at $42.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SNWV's P/E ratio is -5.19. In terms of profitability, PACB's ROE is -1.89%, compared to SNWV's ROE of +1.45%. Regarding short-term risk, PACB is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check SNWV's competition here
PACB vs RXST Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, RXST has a market cap of 352.3M. Regarding current trading prices, PACB is priced at $1.32, while RXST trades at $8.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas RXST's P/E ratio is -10.76. In terms of profitability, PACB's ROE is -1.89%, compared to RXST's ROE of -0.12%. Regarding short-term risk, PACB is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check RXST's competition here
PACB vs CLPT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, CLPT has a market cap of 298.5M. Regarding current trading prices, PACB is priced at $1.32, while CLPT trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas CLPT's P/E ratio is -13.12. In terms of profitability, PACB's ROE is -1.89%, compared to CLPT's ROE of -0.94%. Regarding short-term risk, PACB is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check CLPT's competition here
PACB vs BWAY Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BWAY has a market cap of 290.3M. Regarding current trading prices, PACB is priced at $1.32, while BWAY trades at $15.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BWAY's P/E ratio is 54.86. In terms of profitability, PACB's ROE is -1.89%, compared to BWAY's ROE of +0.09%. Regarding short-term risk, PACB is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check BWAY's competition here
PACB vs TCMD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, TCMD has a market cap of 289.8M. Regarding current trading prices, PACB is priced at $1.32, while TCMD trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas TCMD's P/E ratio is 20.97. In terms of profitability, PACB's ROE is -1.89%, compared to TCMD's ROE of +0.07%. Regarding short-term risk, PACB is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check TCMD's competition here
PACB vs NPCE Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, NPCE has a market cap of 286.2M. Regarding current trading prices, PACB is priced at $1.32, while NPCE trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas NPCE's P/E ratio is -10.55. In terms of profitability, PACB's ROE is -1.89%, compared to NPCE's ROE of -1.12%. Regarding short-term risk, PACB is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check NPCE's competition here
PACB vs VMD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, VMD has a market cap of 275M. Regarding current trading prices, PACB is priced at $1.32, while VMD trades at $7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas VMD's P/E ratio is 20.85. In terms of profitability, PACB's ROE is -1.89%, compared to VMD's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check VMD's competition here
PACB vs CATX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, CATX has a market cap of 256.2M. Regarding current trading prices, PACB is priced at $1.32, while CATX trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas CATX's P/E ratio is -2.52. In terms of profitability, PACB's ROE is -1.89%, compared to CATX's ROE of -0.32%. Regarding short-term risk, PACB is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check CATX's competition here
PACB vs NNOX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, NNOX has a market cap of 248M. Regarding current trading prices, PACB is priced at $1.32, while NNOX trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas NNOX's P/E ratio is -4.32. In terms of profitability, PACB's ROE is -1.89%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, PACB is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check NNOX's competition here
PACB vs CERS Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, CERS has a market cap of 245.4M. Regarding current trading prices, PACB is priced at $1.32, while CERS trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas CERS's P/E ratio is -12.80. In terms of profitability, PACB's ROE is -1.89%, compared to CERS's ROE of -0.34%. Regarding short-term risk, PACB is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check CERS's competition here
PACB vs OM Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, OM has a market cap of 243.8M. Regarding current trading prices, PACB is priced at $1.32, while OM trades at $13.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas OM's P/E ratio is -0.73. In terms of profitability, PACB's ROE is -1.89%, compared to OM's ROE of -0.98%. Regarding short-term risk, PACB is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check OM's competition here
PACB vs MASS Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, MASS has a market cap of 226.3M. Regarding current trading prices, PACB is priced at $1.32, while MASS trades at $6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas MASS's P/E ratio is -2.66. In terms of profitability, PACB's ROE is -1.89%, compared to MASS's ROE of -0.13%. Regarding short-term risk, PACB is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check MASS's competition here
PACB vs NVRO Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PACB is priced at $1.32, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PACB's ROE is -1.89%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PACB is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check NVRO's competition here
PACB vs SGHT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, SGHT has a market cap of 220.5M. Regarding current trading prices, PACB is priced at $1.32, while SGHT trades at $4.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas SGHT's P/E ratio is -4.39. In terms of profitability, PACB's ROE is -1.89%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, PACB is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check SGHT's competition here
PACB vs QTRX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, QTRX has a market cap of 217M. Regarding current trading prices, PACB is priced at $1.32, while QTRX trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas QTRX's P/E ratio is -2.58. In terms of profitability, PACB's ROE is -1.89%, compared to QTRX's ROE of -0.22%. Regarding short-term risk, PACB is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check QTRX's competition here
PACB vs EYES Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, PACB is priced at $1.32, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas EYES's P/E ratio is N/A. In terms of profitability, PACB's ROE is -1.89%, compared to EYES's ROE of -0.26%. Regarding short-term risk, PACB is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check EYES's competition here
PACB vs INGN Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, INGN has a market cap of 208.5M. Regarding current trading prices, PACB is priced at $1.32, while INGN trades at $7.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas INGN's P/E ratio is -7.27. In terms of profitability, PACB's ROE is -1.89%, compared to INGN's ROE of -0.14%. Regarding short-term risk, PACB is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check INGN's competition here
PACB vs MGRM Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, MGRM has a market cap of 194.9M. Regarding current trading prices, PACB is priced at $1.32, while MGRM trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas MGRM's P/E ratio is -9.98. In terms of profitability, PACB's ROE is -1.89%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, PACB is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check MGRM's competition here
PACB vs CVRX Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, CVRX has a market cap of 194.8M. Regarding current trading prices, PACB is priced at $1.32, while CVRX trades at $7.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas CVRX's P/E ratio is -3.62. In terms of profitability, PACB's ROE is -1.89%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, PACB is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check CVRX's competition here
PACB vs TLSI Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, TLSI has a market cap of 187.2M. Regarding current trading prices, PACB is priced at $1.32, while TLSI trades at $4.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas TLSI's P/E ratio is -4.29. In terms of profitability, PACB's ROE is -1.89%, compared to TLSI's ROE of +1.27%. Regarding short-term risk, PACB is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check TLSI's competition here
PACB vs ELMD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ELMD has a market cap of 169.5M. Regarding current trading prices, PACB is priced at $1.32, while ELMD trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ELMD's P/E ratio is 25.58. In terms of profitability, PACB's ROE is -1.89%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, PACB is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check ELMD's competition here
PACB vs BSGM Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, BSGM has a market cap of 166.1M. Regarding current trading prices, PACB is priced at $1.32, while BSGM trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas BSGM's P/E ratio is -5.05. In terms of profitability, PACB's ROE is -1.89%, compared to BSGM's ROE of +41.24%. Regarding short-term risk, PACB is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check BSGM's competition here
PACB vs LNSR Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, LNSR has a market cap of 151.1M. Regarding current trading prices, PACB is priced at $1.32, while LNSR trades at $12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas LNSR's P/E ratio is -3.01. In terms of profitability, PACB's ROE is -1.89%, compared to LNSR's ROE of +51.79%. Regarding short-term risk, PACB is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check LNSR's competition here
PACB vs MXCT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, MXCT has a market cap of 148.2M. Regarding current trading prices, PACB is priced at $1.32, while MXCT trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas MXCT's P/E ratio is -3.31. In terms of profitability, PACB's ROE is -1.89%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, PACB is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check MXCT's competition here
PACB vs PROF Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, PROF has a market cap of 140.3M. Regarding current trading prices, PACB is priced at $1.32, while PROF trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas PROF's P/E ratio is -3.22. In terms of profitability, PACB's ROE is -1.89%, compared to PROF's ROE of -0.91%. Regarding short-term risk, PACB is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check PROF's competition here
PACB vs AVR Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, AVR has a market cap of 133.4M. Regarding current trading prices, PACB is priced at $1.32, while AVR trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas AVR's P/E ratio is -1.21. In terms of profitability, PACB's ROE is -1.89%, compared to AVR's ROE of -2.52%. Regarding short-term risk, PACB is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check AVR's competition here
PACB vs ANIK Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ANIK has a market cap of 131.6M. Regarding current trading prices, PACB is priced at $1.32, while ANIK trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ANIK's P/E ratio is -10.14. In terms of profitability, PACB's ROE is -1.89%, compared to ANIK's ROE of -0.38%. Regarding short-term risk, PACB is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check ANIK's competition here
PACB vs LUCD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, LUCD has a market cap of 125.8M. Regarding current trading prices, PACB is priced at $1.32, while LUCD trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas LUCD's P/E ratio is -1.22. In terms of profitability, PACB's ROE is -1.89%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PACB is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check LUCD's competition here
PACB vs OWLT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, OWLT has a market cap of 125.8M. Regarding current trading prices, PACB is priced at $1.32, while OWLT trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas OWLT's P/E ratio is -1.97. In terms of profitability, PACB's ROE is -1.89%, compared to OWLT's ROE of +2.12%. Regarding short-term risk, PACB is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check OWLT's competition here
PACB vs RCEL Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, RCEL has a market cap of 123.9M. Regarding current trading prices, PACB is priced at $1.32, while RCEL trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas RCEL's P/E ratio is -2.36. In terms of profitability, PACB's ROE is -1.89%, compared to RCEL's ROE of +279.91%. Regarding short-term risk, PACB is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check RCEL's competition here
PACB vs RPID Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, RPID has a market cap of 116.2M. Regarding current trading prices, PACB is priced at $1.32, while RPID trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas RPID's P/E ratio is -2.64. In terms of profitability, PACB's ROE is -1.89%, compared to RPID's ROE of -0.63%. Regarding short-term risk, PACB is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check RPID's competition here
PACB vs QIPT Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, QIPT has a market cap of 113.4M. Regarding current trading prices, PACB is priced at $1.32, while QIPT trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas QIPT's P/E ratio is -10.87. In terms of profitability, PACB's ROE is -1.89%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PACB is less volatile compared to QIPT. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check QIPT's competition here
PACB vs ICAD Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PACB is priced at $1.32, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PACB's ROE is -1.89%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, PACB is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check ICAD's competition here
PACB vs NSPR Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, NSPR has a market cap of 100.1M. Regarding current trading prices, PACB is priced at $1.32, while NSPR trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas NSPR's P/E ratio is -2.96. In terms of profitability, PACB's ROE is -1.89%, compared to NSPR's ROE of -1.31%. Regarding short-term risk, PACB is less volatile compared to NSPR. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check NSPR's competition here
PACB vs HJLI Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PACB is priced at $1.32, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas HJLI's P/E ratio is N/A. In terms of profitability, PACB's ROE is -1.89%, compared to HJLI's ROE of -0.00%. Regarding short-term risk, PACB is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for PACB.Check HJLI's competition here
PACB vs HYPR Comparison August 2025
PACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PACB stands at 396.5M. In comparison, HYPR has a market cap of 98.2M. Regarding current trading prices, PACB is priced at $1.32, while HYPR trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PACB currently has a P/E ratio of -0.59, whereas HYPR's P/E ratio is -2.40. In terms of profitability, PACB's ROE is -1.89%, compared to HYPR's ROE of -0.85%. Regarding short-term risk, PACB is more volatile compared to HYPR. This indicates potentially higher risk in terms of short-term price fluctuations for PACB.Check HYPR's competition here